Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 447-449

  Liu, Yang ^a   Tabarroki, Ali ^a   Billings, Steven ^b   Visconte, Valeria ^a   Rogers, Heesun J ^b   Hasrouni, Edy ^a   Englehaupt, Ricki ^a   Kalaycio, Matt ^a   Sekeres, Mikkael A ^a   Saunthararajah, Yogen ^a   Tiu, Ramon V ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DOXYCYCLINE; ERYTHROPOIETIN; HEMOGLOBIN; PREDNISONE; STEROID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 20; CHROMOSOME 7; CHROMOSOME DELETION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; NIGHT SWEAT; ORAL BLEEDING; PAPULE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY; SPLENOMEGALY; STEROID THERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RISK FACTORS; SWEET SYNDROME; TREATMENT OUTCOME;

EID: 84896983937     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.802315     Document Type: Letter

References (17)

1. Quintas-Cardama A., Tong W, Kantarjian H., et al A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia 2008; 22:965-970. (Pubitemid 351689878)
2. Mesa RA, Verstovsek S, Rivera C., et al 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009;23:180-182.
3. Mahfouz RZ, Rickki E, Juersivich J.A., et al Non-cytotoxic differentiation therapy based on mechanism of disease produces complete remission in myelodysplastic syndromes (MDS) with high risk cytogenetics. Blood 2012;120(Suppl. 1): Abstract 1696.
4. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol 1964;76:349-356.
5. Cohen PR. Sweet's syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34.
6. Alencar C, Abramowtiz M, Parekh S., et al Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol 2009;84:688-689.
7. Pang A, Tan KB, Aw D, et al A case of Sweet's syndrome due to 5-azacytidine and vorinostat in a patient with NK/T cell lymphoma. Cutan Ocul Toxicol 2012;31:64-66.
8. Trickett HB, Cumpston A, Craig M. Azacitidine-associated Sweet's syndrome. Am J Health Syst Pharm 2012;69:869-871.
9. Che Y, Tanioka M, Matsumura Y., et al Splenic irradiation-induced Sweet's syndrome associated with preceding myelofibrosis. Clin Exp Dermatol 2008;33:200-201. (Pubitemid 351197202)
10. Brodkin RH, Schwartz RA Sweet's syndrome with myelofibrosis and leukemia: partial response to interferon. Dermatology 1995;190: 160-163.
11. Walker DC, Cohen PR Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: casereportand review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996. 34: 918-923. (Pubitemid 26143882)
12. Tintle S, Patel V, Ruskin A., et al Azacitidine: a new medication associated with Sweet syndrome. J Am Acad Dermatol 2011;64: e77-e79.
13. Stein BL, Williams DM, O'Keefe C, et al Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011;96:1462-1469.
14. Saunthararajah Y, Triozzi P, Rini B., et al p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol 2012;39:97-108.
15. Olivieri NF, Saunthararajah Y, Thayalasu than V, et al A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood 2011;118:2708-2711.
16. Saunthararajah Y, Hillery CA, Lavelle D, et al Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003, 102:3865-3870. (Pubitemid 37486964)
17. Odenike OM, Godwin JE, van Beisen K, et al Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. Blood 2008;112(Suppl. 1): Abstract 2809.